Pharma Companies

 Piramal Healthcare and Cipla signed a definitive agreement for purchase of all intellectual property rights in India related to i-pill brand of Cipla. The deal was sealed for an aggregate consideration of Rs 95 crore. i-pill brand features in the top-300 pharmaceutical products and had sales of Rs 30.92 crore as per ORG IMS for the last twelve months.

 Bangalore, Mar, 23, 2010: Syngene International, a subsidiary of Biocon has entered into a discovery and development collaboration with Endo Pharmaceuticals, USA to develop novel biological therapeutic molecules against cancer.

Under the agreement Endo will retain all rights to the molecules developed, while Syngene International will receive research fees, milestone payments and success fees from Endo.